Literature DB >> 1602282

New aspects of asthma.

P J Barnes1.   

Abstract

It has now become apparent that asthma, even in its mildest clinical manifestation, is a chronic inflammatory condition of the airways. There have been important advances in understanding the special features of inflammation in asthmatic airways and the role of critical inflammatory cells such as mast cells (important in the acute inflammatory response) and eosinophils, macrophages and T-lymphocytes (involved in the chronic inflammatory response). Many inflammatory mediators have been implicated in asthma, and the development of mediator antagonists suggests that sulphidopeptide leukotrienes may play an important role in bronchoconstrictor responses. Cytokines released from many different cells in the airways are likely to be important in orchestrating and perpetuating the chronic inflammatory response. Chronic inflammation has effects on airway vessels, mucus secretion, smooth muscle and nerves, with evidence to suggest that there are structural changes which may lead to persistent airway abnormalities. The therapeutic implication of these new discoveries is that much earlier use of anti-inflammatory treatments (such as inhaled steroids) is preferable to reliance on bronchodilators which do not control the underlying inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602282     DOI: 10.1111/j.1365-2796.1992.tb00960.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Relationship between the development of bronchial hyperresponsiveness and the airway eosinophilia in guinea pigs following injection with Sephadex beads.

Authors:  K Maghni; M J Simard; S Cloutier; D Arseneault; P Sirois
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

2.  Airway platelet activation is associated with airway eosinophilic inflammation in asthma.

Authors:  Angela S Benton; Nikila Kumar; Jennifer Lerner; Andrew A Wiles; Matthew Foerster; Stephen J Teach; Robert J Freishtat
Journal:  J Investig Med       Date:  2010-12       Impact factor: 2.895

3.  Potent selective nonpeptidic inhibitors of human lung tryptase.

Authors:  L E Burgess; B J Newhouse; P Ibrahim; J Rizzi; M A Kashem; A Hartman; B J Brandhuber; C D Wright; D S Thomson; G P Vigers; K Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

4.  Anti-inflammatory, immunomodulatory, and heme oxygenase-1 inhibitory activities of ravan napas, a formulation of uighur traditional medicine, in a rat model of allergic asthma.

Authors:  Sajida Abdureyim; Nurmuhammat Amat; Anwar Umar; Halmurat Upur; Benedicte Berke; Nicholas Moore
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-05       Impact factor: 2.629

5.  Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.

Authors:  A Hatzelmann; H Tenor; C Schudt
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

6.  Efficacy and Safety of Modified Pranlukast (Prakanon(®)) Compared with Pranlukast (Onon(®)): A Randomized, Open-Label, Crossover Study.

Authors:  Seo W Kim; Hunam Kim; Yon J Ryu; Jin H Lee; Sung S Shim; Yoo K Kim; Jung H Chang
Journal:  Open Respir Med J       Date:  2016-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.